A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.Published in:2017By:Papadopoulos, K P;El-Rayes, B F;Tolcher, A W;Patnaik, A;Rasco, D W;Harvey, R D;LoRusso, P M;Sachdev, J C;Abbadessa, G;Savage, R E;Hall, T;Schwartz, B;Wang, Y;Kazakin, J;Shaib, W LPublication type:journal article